HRP20110702T1 - Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora - Google Patents

Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora Download PDF

Info

Publication number
HRP20110702T1
HRP20110702T1 HR20110702T HRP20110702T HRP20110702T1 HR P20110702 T1 HRP20110702 T1 HR P20110702T1 HR 20110702 T HR20110702 T HR 20110702T HR P20110702 T HRP20110702 T HR P20110702T HR P20110702 T1 HRP20110702 T1 HR P20110702T1
Authority
HR
Croatia
Prior art keywords
compound
salt
image
compound according
formula
Prior art date
Application number
HR20110702T
Other languages
English (en)
Croatian (hr)
Inventor
Venkateswaran Devraj Rajesh
A. De Crescenzo Gary
Hu Xiao
Dewayne Jerome Kevin
Gerard Obukowicz Mark
Olson Lisa
Vincent Rucker Paul
Keith Webber Ronald
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20110702T1 publication Critical patent/HRP20110702T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
HR20110702T 2007-02-02 2008-01-25 Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora HRP20110702T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
PCT/IB2008/000229 WO2008093227A1 (en) 2007-02-02 2008-01-25 Tricyclic compounds and their use as glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
HRP20110702T1 true HRP20110702T1 (hr) 2011-10-31

Family

ID=39315208

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110702T HRP20110702T1 (hr) 2007-02-02 2008-01-25 Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora

Country Status (42)

Country Link
US (7) US7598231B2 (enExample)
EP (1) EP2114970B1 (enExample)
JP (1) JP4599462B2 (enExample)
KR (2) KR101107949B1 (enExample)
CN (2) CN101616925B (enExample)
AP (1) AP2455A (enExample)
AR (2) AR065134A1 (enExample)
AT (1) ATE518872T1 (enExample)
AU (1) AU2008211613B2 (enExample)
BR (1) BRPI0808634A2 (enExample)
CA (1) CA2676670C (enExample)
CL (2) CL2008000329A1 (enExample)
CO (2) CO6220937A2 (enExample)
CR (2) CR10948A (enExample)
CU (2) CU23824A3 (enExample)
CY (2) CY1110962T1 (enExample)
DK (1) DK2114970T3 (enExample)
DO (1) DOP2009000190A (enExample)
EA (1) EA016494B1 (enExample)
EC (2) ECSP099553A (enExample)
ES (2) ES2368286T3 (enExample)
GE (2) GEP20125404B (enExample)
GT (2) GT200900210A (enExample)
HN (2) HN2008000179A (enExample)
HR (1) HRP20110702T1 (enExample)
IL (1) IL199972A (enExample)
MA (2) MA31117B1 (enExample)
MX (1) MX2009008284A (enExample)
MY (3) MY153057A (enExample)
NI (2) NI200900149A (enExample)
NZ (1) NZ578638A (enExample)
PE (2) PE20081736A1 (enExample)
PL (1) PL2114970T3 (enExample)
PT (2) PT2114970E (enExample)
RS (2) RS51970B (enExample)
SI (1) SI2114970T1 (enExample)
SV (2) SV2009003346A (enExample)
TN (1) TN2009000324A1 (enExample)
TW (2) TWI347842B (enExample)
UA (2) UA94639C2 (enExample)
WO (1) WO2008093227A1 (enExample)
ZA (2) ZA200906064B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200184T7 (es) 1996-07-24 2015-02-10 Warner-Lambert Company Llc Isobutilgaba y sus derivados para el tratamiento del dolor
MY153057A (en) * 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
PT2307375E (pt) * 2008-07-28 2015-01-14 Pfizer Compostos da fenantrenona, composições e métodos
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
AU2011293193A1 (en) * 2010-08-27 2013-02-14 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) * 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
CN106413673A (zh) 2014-05-16 2017-02-15 利奎德股份有限公司 角蛋白处理制剂和方法
ES2848977T5 (es) 2014-10-20 2024-06-06 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
CN113350352B (zh) * 2015-03-23 2024-09-10 天莅生物科技私人有限公司 呼吸性疾病的治疗
US10709707B2 (en) 2016-04-07 2020-07-14 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3877382A4 (en) 2018-11-07 2022-07-27 The University of Melbourne NOVEL COMPOUNDS TO TREAT RESPIRATORY DISEASES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EE05584B1 (et) 1999-04-30 2012-10-15 Pfizer Products Inc. Glkokortikoidretseptori modulaatorid
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
ES2262612T3 (es) * 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
ATE303369T1 (de) 2000-10-30 2005-09-15 Pfizer Prod Inc Glucocorticoid rezeptor modulatoren
JP2004515026A (ja) * 2000-11-20 2004-05-20 シーゲイト　テクノロジー　エルエルシー ディスク・ドライブへのｒｆｉｄタグ取付け
CA2450748A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CN1868480A (zh) 2001-08-31 2006-11-29 科塞普特治疗公司 抑制成年唐氏综合症患者认知退化的方法
JP4280631B2 (ja) 2001-09-27 2009-06-17 ユニベルシテ・ド・リエージュ ピリジンスルホンアミド誘導体、その生産方法、およびその使用
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2004004653A2 (en) 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferon-alpha therapy
BR0312575A (pt) * 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
US7361646B2 (en) 2002-11-05 2008-04-22 Corcept Therapeutics, Inc. Methods for treating gastroesophageal reflux disease
JP2006516651A (ja) 2003-02-04 2006-07-06 コーセプト セラピューティクス， インコーポレイテッド 産後精神病の処置のための抗糖質コルチコイド
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
EP1682150B1 (en) * 2003-11-10 2012-12-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
JP2007511501A (ja) * 2003-11-13 2007-05-10 ファイザー・プロダクツ・インク グルココルチコイド受容体調節剤として有用なオクタヒドロフェナンスレンヒドラジド誘導体
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
EP2012796A4 (en) 2006-05-02 2010-08-11 Corcept Therapeutics Inc USE OF GLUCOCORTICOID TYPE II RECEPTOR ANTAGONISTS TO TREAT PATIENT DEPRESSION WITH IL-2
MY153057A (en) * 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
DK2114888T3 (da) * 2007-02-02 2011-01-24 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glu-cocorticoid-receptor-modulatorer

Also Published As

Publication number Publication date
TWI347842B (en) 2011-09-01
CU23848B1 (es) 2012-10-15
KR101107949B1 (ko) 2012-02-08
ECSP099552A (es) 2009-08-28
AU2008211613A1 (en) 2008-08-07
KR20090108115A (ko) 2009-10-14
CU20090133A7 (es) 2011-10-31
EA016494B1 (ru) 2012-05-30
CN101616896A (zh) 2009-12-30
CY1111758T1 (el) 2015-10-07
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
TWI373466B (en) 2012-10-01
MA31158B1 (fr) 2010-02-01
US20120088802A9 (en) 2012-04-12
EP2114970A1 (en) 2009-11-11
KR20090107080A (ko) 2009-10-12
US7598231B2 (en) 2009-10-06
NZ578638A (en) 2010-12-24
KR101114682B1 (ko) 2012-03-14
US20080188443A1 (en) 2008-08-07
ZA200906064B (en) 2010-05-26
CA2676670C (en) 2012-03-13
TW200846325A (en) 2008-12-01
PE20090113A1 (es) 2009-02-13
AR065134A1 (es) 2009-05-20
MY153057A (en) 2014-12-31
US7547714B2 (en) 2009-06-16
HN2008000179A (es) 2010-06-09
IL199972A (en) 2013-09-30
ZA200906060B (en) 2010-05-26
CU23824A3 (es) 2011-10-31
ATE518872T1 (de) 2011-08-15
UA94639C2 (ru) 2011-05-25
AR065135A1 (es) 2009-05-20
GEP20125404B (en) 2012-02-27
CO6220937A2 (es) 2010-11-19
US8445520B2 (en) 2013-05-21
US20120095062A1 (en) 2012-04-19
MA31117B1 (fr) 2010-01-04
US7786097B2 (en) 2010-08-31
ES2353822T3 (es) 2011-03-07
PE20081736A1 (es) 2008-11-28
MY146087A (en) 2012-06-29
CO6190603A2 (es) 2010-08-19
CN101616925A (zh) 2009-12-30
US20100286214A1 (en) 2010-11-11
EA200970666A1 (ru) 2010-02-26
ECSP099553A (es) 2009-08-28
HN2008000178A (es) 2011-02-25
PL2114970T3 (pl) 2011-11-30
TN2009000324A1 (fr) 2010-12-31
WO2008093227A1 (en) 2008-08-07
US20140316139A1 (en) 2014-10-23
CN101616925B (zh) 2012-05-23
HK1135108A1 (en) 2010-05-28
AP2455A (en) 2012-08-31
CR10949A (es) 2009-08-07
US20140142316A1 (en) 2014-05-22
UA95332C2 (uk) 2011-07-25
SV2009003346A (es) 2010-04-13
AP2009004942A0 (en) 2009-08-31
SI2114970T1 (sl) 2011-11-30
US20090281148A1 (en) 2009-11-12
US8158660B2 (en) 2012-04-17
NI200900149A (es) 2010-02-15
CL2008000330A1 (es) 2008-08-08
PT2114970E (pt) 2011-09-22
NI200900148A (es) 2010-02-15
ES2368286T3 (es) 2011-11-16
CN101616896B (zh) 2012-07-04
DOP2009000190A (es) 2009-08-31
EP2114970B1 (en) 2011-08-03
GEP20125426B (en) 2012-03-26
DK2114970T3 (da) 2011-09-19
SV2009003349A (es) 2010-04-13
MY148780A (en) 2013-05-31
US8901310B2 (en) 2014-12-02
IL199972A0 (en) 2010-04-15
RS51970B (sr) 2012-02-29
RS51646B (sr) 2011-10-31
US20080312294A1 (en) 2008-12-18
CU20090132A7 (es) 2011-10-14
TW200838514A (en) 2008-10-01
CA2676670A1 (en) 2008-08-07
PT2114888E (pt) 2011-01-04
GT200900210A (es) 2010-04-05
CL2008000329A1 (es) 2008-08-08
CR10948A (es) 2009-08-07
GT200900209A (es) 2010-07-22
BRPI0808634A2 (pt) 2014-08-05
MX2009008284A (es) 2009-08-12
JP4599462B2 (ja) 2010-12-15
JP2010517990A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
HRP20110702T1 (hr) Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora
HRP20100726T1 (hr) Triciklički spojevi i njihova upotreba kao modulatora glukokortikoidnih receptora
JP2010517990A5 (enExample)
EA201170251A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
ES2566391T3 (es) Composiciones a base de hidrofluoroolefinas
EA201170374A1 (ru) Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
BRPI0813140C1 (pt) método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário
EA201592252A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
EA200901435A1 (ru) Гидравлические цементы, содержащие композиции карбонатных соединений
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
HRP20140394T1 (hr) Tri-aril spojevi i sastavi koji ih ukljuäśuju
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
WO2007085451A3 (en) 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents
GB201203582D0 (en) Sulfonamide-containing photoresist compositions and methods of use
Liu et al. The dual-effects of LaCl3 on the proliferation, osteogenic differentiation, and mineralization of MC3T3-E1 cells
MX2008010481A (es) Compuestos que tienen afinado para el receptor f-ht6.
BR112016024844A2 (pt) materiais de concreto com reologia modificada, métodos de fabricação e usos dos mesmos
BRPI0712142A8 (pt) Formulações farmacêuticas para a liberação prolongada de princípio(s) ativo(s), bem como suas aplicações, especialmente aplicações terapêuticas
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
BRPI0711310B8 (pt) composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo
HRP20060298A2 (hr) Ciljajući spojevi piperidinila koji selektivno vežu integrine
BRPI0711343A2 (pt) composições de graxa para juntas de velocidade constante